

# Filipe B. Rodrigues

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5061323/publications.pdf>

Version: 2024-02-01

85  
papers

2,187  
citations

331259

21  
h-index

264894

42  
g-index

94  
all docs

94  
docs citations

94  
times ranked

2880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , The, 2017, 16, 601-609.	4.9	272
2	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 353, i1754.	3.0	157
3	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	134
4	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2020, 19, 502-512.	4.9	122
5	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. <i>Heart</i> , 2015, 101, 1204-1211.	1.2	106
6	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2017, 12, CD003633.	1.5	92
7	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 737-742.	0.8	65
8	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018, 90, e717-e723.	1.5	65
9	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	64
10	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , 2016, 139, 22-25.	2.1	58
11	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , 2016, 11, e0163479.	1.1	58
12	Huntington's Disease Clinical Trials Corner: February 2018. <i>Journal of Huntington's Disease</i> , 2018, 7, 89-98.	0.9	56
13	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntington's Disease</i> , 2017, 6, 157-163.	0.9	50
14	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 582-585.	0.8	48
15	Huntington's Disease Clinical Trials Corner: April 2020. <i>Journal of Huntington's Disease</i> , 2020, 9, 185-197.	0.9	47
16	Placebo and nocebo responses in restless legs syndrome. <i>Neurology</i> , 2017, 88, 2216-2224.	1.5	46
17	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD012405.	1.5	44
18	Botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016, 2016, CD004315.	1.5	36

#	ARTICLE	IF	CITATIONS
19	Clinical Trials Corner: September 2017. <i>Journal of Huntington's Disease</i> , 2017, 6, 255-263.	0.9	33
20	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016, 2016, CD004314.	1.5	31
21	Huntington's Disease Clinical Trials Corner: June 2019. <i>Journal of Huntington's Disease</i> , 2019, 8, 363-371.	0.9	30
22	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 93-104.	1.1	28
23	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 4260.	1.6	25
24	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	2.2	23
25	Morphine in acute coronary syndrome: systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025232.	0.8	23
26	Huntington's Disease Clinical Trials Corner: January 2019. <i>Journal of Huntington's Disease</i> , 2019, 8, 115-125.	0.9	23
27	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD003633.	1.5	23
28	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 361-372.	0.8	22
29	Huntington's Disease Clinical Trials Corner: August 2018. <i>Journal of Huntington's Disease</i> , 2018, 7, 279-286.	0.9	22
30	Biofluid Biomarkers in Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018, 1780, 329-396.	0.4	21
31	Anti-TNF Drugs for Chronic Uveitis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Medicine</i> , 2019, 6, 104.	1.2	21
32	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis: a systematic review. <i>Acta Ophthalmologica</i> , 2018, 96, e665-e675.	0.6	20
33	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 52-60.	0.8	20
34	An MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	2.2	19
35	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , 2021, 158, 539-553.	2.1	18
36	Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review. <i>Renal Failure</i> , 2016, 38, 493-502.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2018, 41, 77-86.	1.4	17
38	Intracerebral hemorrhage as a manifestation of cerebral hyperperfusion syndrome after carotid revascularization: systematic review and meta-analysis. <i>Acta Neurochirurgica</i> , 2017, 159, 2089-2097.	0.9	16
39	Huntington's Disease Clinical Trials Corner: April 2022. <i>Journal of Huntington's Disease</i> , 2022, 11, 105-118.	0.9	16
40	A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32997.	2.1	15
41	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 302-311.	0.8	14
42	Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 19.	2.2	13
43	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , 2020, 2020, CD004900.	1.5	13
44	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. <i>BJU International</i> , 2021, 128, 722-727.	1.3	13
45	Opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 445-453.	0.9	12
46	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021, 11, 3481.	1.6	12
47	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 16-19.	1.1	11
48	Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. <i>Movement Disorders</i> , 2022, 37, 1526-1531.	2.2	9
49	Frequency of post-stroke electroencephalographic epileptiform activity " a systematic review and meta-analysis of observational studies. <i>European Stroke Journal</i> , 2017, 2, 361-368.	2.7	8
50	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , 2020, 15, e0233820.	1.1	8
51	Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. <i>Clinical Medicine Insights Blood Disorders</i> , 2017, 10, 1179545X1770466.	0.3	7
52	Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource. <i>Journal of Huntington's Disease</i> , 2022, 11, 59-69.	0.9	7
53	Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review. <i>Journal of Critical Care</i> , 2016, 33, 271-273.	1.0	6
54	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , 2020, 2020, CD004899.	1.5	6

#	ARTICLE	IF	CITATIONS
55	Natural history and burden of Huntington's disease in the <scp>UK</scp>: A <scp>population-based</scp> cohort study. <i>European Journal of Neurology</i> , 2022, 29, 2249-2257.	1.7	6
56	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast <scp>MRI</scp>. <i>European Journal of Neuroscience</i> , 2019, 49, 1632-1639.	1.2	5
57	Strategies to minimize placebo effects in research investigations. <i>International Review of Neurobiology</i> , 2020, 153, 49-70.	0.9	5
58	Psychogenic non-epileptic seizures in early Huntington's disease. <i>Practical Neurology</i> , 2016, 16, 452-454.	0.5	4
59	Her Aching Bones: Atypical Parathyroid Adenoma. <i>American Journal of Medicine</i> , 2016, 129, 260-262.	0.6	2
60	Overall Survival and Causes of Death in Neurodegeneration—An Overlooked and Underreported Theme. <i>JAMA Neurology</i> , 2017, 74, 1379.	4.5	2
61	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 55-60.	1.1	2
62	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. <i>Clinical Neurophysiology</i> , 2020, 131, 106-113.	0.7	2
63	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 233-272.	0.4	1
64	Mechanical Thrombectomy and Functional Outcomes After Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1791.	3.8	1
65	Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series. <i>Canadian Journal of Ophthalmology</i> , 2016, 51, 459-466.	0.4	1
66	Management of Small Renal Masses. <i>Radiology</i> , 2018, 289, 272-273.	3.6	1
67	Managing treatment fluctuations in Parkinson disease. <i>Neurology</i> , 2019, 92, 597-598.	1.5	1
68	Botulinum toxin type A versus anticholinergics for cervical dystonia. <i>The Cochrane Library</i> , 2021, 2021, CD004312.	1.5	1
69	170. Botulinum toxins for focal dystonias: an update of 7 Cochrane systematic reviews. <i>Toxicon</i> , 2015, 93, S53.	0.8	0
70	K4...The cost and value of a huntington's disease multidisciplinary team meeting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A80.2-A80.	0.9	0
71	Bilateral gigantic earlobe keloids. <i>Clinical Medicine</i> , 2016, 16, 91.	0.8	0
72	D4...Prediction of huntington's disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.1-A35.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Deep brain stimulation for dystonia. The Cochrane Library, 2016, , .	1.5	0
74	PO104â€¦Placebo and nocebo responses in rls: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A39.1-A39.	0.9	0
75	D10â€¦Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
76	D09â€¦Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
77	Physician perception versus true efficacy of tetrabenazine for Huntingtonâ€™s disease. Current Medical Research and Opinion, 2018, 34, 1537-1538.	0.9	0
78	The risks of converting post-hoc findings into primary outcomes in subsequent trials. Annals of Translational Medicine, 2019, 7, S337-S337.	0.7	0
79	F05â€¦Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
80	E07â€¦Cerebrospinal fluid flow dynamics in huntingtonâ€™s disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , .		0
81	D08â€¦Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
82	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
83	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
84	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
85	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0